SAP's Strategic Pivot Amid Market Pressures

SAP counters stock decline with a €10 billion share repurchase plan and a strategic investment in Avelios Medical, pivoting its healthcare strategy towards AI and platforms.

The software giant SAP is implementing a dual-pronged strategy to address investor concerns, as its shares continue to face significant downward pressure. In a week marked by strategic announcements, the Walldorf-based company revealed a key investment in the health technology sector alongside a substantial new share repurchase authorization.

Share Buyback and Dividend Proposed

In a direct response to the recent stock performance, SAP's executive and supervisory boards have put forward measures aimed at returning value to shareholders. A dividend proposal of €2.50 per share for the concluded fiscal year has been announced. More significantly, the company has authorized a massive share repurchase program worth up to €10 billion, scheduled to run from February 2026 through the end of 2027.

This move comes as SAP's stock struggles to find a footing. Closing at €170.32, the share price now sits approximately 37% below its 52-week high recorded in June of last year. Since the beginning of the current year alone, the equity has shed over 15% of its value.

A Strategic HealthTech Investment

Concurrently, SAP has made a strategic foray into the healthcare technology space by taking a stake in Munich-based specialist Avelios Medical. The financial details of this investment remain confidential. This strategic shift is directly tied to SAP's previously announced plan to exit the traditional hospital information system (IS-H) market by 2030, a decision that will necessitate IT infrastructure changes for hundreds of clinics.

Through this partnership, SAP is securing a pivotal role in the future architecture for these clients. Avelios Medical's software operates on the SAP Business Technology Platform (BTP). This positions the DAX-listed corporation not as a mere applications developer, but as a future platform provider for data and artificial intelligence within the healthcare industry.

Operational Focus and Market Skepticism

The backdrop for these strategic actions is a market disappointed by the cloud order backlog figures for the fourth quarter of 2025. This overshadowed otherwise solid annual results, which included a 26% currency-adjusted rise in cloud revenue and a free cash flow that climbed to over €8 billion. The overarching investor fear is that the AI transformation sweeping the software sector could disrupt traditional business models faster than SAP can monetize the new technologies.

Operationally, SAP's focus is now squarely on artificial intelligence. By the fourth quarter, two-thirds of all new cloud contracts already contained AI components.

Conclusion: A Critical Transition Phase

SAP is navigating a complex transitional period. While its 2025 financials were robust, the market is demanding clear evidence of future growth potential in an AI-dominated landscape. The investment in Avelios represents a logical strategic component to maintain relevance in the healthcare market post the IS-H withdrawal. Whether these combined initiatives—the financial engineering of the buyback and the strategic pivot in healthcare—will be sufficient to sustainably reverse the downward trend is a question that may find its answer with the release of the next quarterly figures on April 23, 2026.